TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03520491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg or Nivolumab 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg or Nivolumab 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg or Nivolumab 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy
Description: RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy
Description: RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy
Description: RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy
Description: RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)
Study: NCT03015077

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oral glutamine
Description: L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: in the placebo arm: 15 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
Study: NCT04534127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study: NCT04400253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAATH Intervention
Description: SAATH intervention is a physical activity intervention for South Asian mothers and daughters with group exercise classes and discussion groups.
Study: NCT03548610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nanofat-seeded biological scaffold on surgical defect
Description: Nanofat-seeded biological scaffold in healing larger surgical defects (\>1.5cm) involving the lower limbs
Study: NCT01706952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine
Description: Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline
Description: Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
Study: NCT03430037

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Flavonoid Family

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study: NCT04469465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C5 Inhibitor
Description: Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C5 Inhibitor
Description: Participants will continue to receive their ongoing C5 inhibitor (eculizumab or ravulizumab) therapy according to their usual dose and schedule.
Study: NCT02717949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir/ledipasvir
Description: sofosbuvir ledipasvir fixed dose combination given once a day by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sofosbuvir
Description: sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: ribavirin 1200 mg given orally in divided dose for those \>75kg and 1000 mg in divided dose for those \<75 kg.
Study: NCT03036566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lithium disilicate ceramic (Ivoclar)
Description: Three unit high strength ceramic bridges replacing a single tooth.
Study: NCT00913159

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Lithotripsy (ESWL)
Description: Using electric shock wave to treat urolithiasis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Lithotripsy (ESWL)
Description: Using electric shock wave to treat urolithiasis
Study: NCT04527159

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoraphat Pro / VivaSens
Description: desensitizing agents for treatment of dentinal hypersensitivity
Study: NCT01814917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colestilan
Description: body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBPB
Study: NCT04170569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga Practice and Program: Yoga practice consisted of 10 weeks. Yoga practice involved following stages; 5-minute breathing exercises in standing or sitting position, 40-minute postpartum period specific asanas and last 15- minute deep relaxation in lying position were made by the researcher.
Study: NCT03130777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards Alterra Adaptive Prestent with SAPIEN 3 THV
Description: The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards Alterra Adaptive Prestent with SAPIEN 3 THV
Description: The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.
Study: NCT03683719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application.
Study: NCT03950024

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: functional brain MRI
Description: The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: functional brain MRI
Description: The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
Study: NCT03738904

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS
Description: Gabapentin Acetaminophen Ketoroloac IV (intraop) and PO Dexamethasone (included with benzocaine in local anesthesia) Oxycodone PO Polyethylene glycol

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Oxcodone PO Ketorolac IV only (intraop)
Study: NCT01587326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: escitalopram 10 mg/d to 20 mg/d
Study: NCT03708341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Systematic daily administration of melatonin 5 mg during patient's ICU stay

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Systematic daily administration of placebo during patient's ICU stay
Study: NCT01316848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tivozanib
Description: tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
Study: NCT03683719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application.
Study: NCT03683719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delgocitinib cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study: NCT03260816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Parent-Child Interaction Therapy (I-PCIT)
Description: Families assigned to the Internet-delivered Parent-Child Interaction Therapy (I-PCIT) group will receive Internet-delivered weekly sessions of a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referrals as Usual (RAU)
Description: Families assigned to RAU will participate in services referred by their Early Steps team, as per usual care.
Study: NCT03140527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active
Study: NCT03637751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: Trier Social Stress Test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control condition
Description: In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
Study: NCT03417297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: Participants will undergo high intensity focused ultrasound surgery utilizing magnetic resonance (MR) imaging guidance using a 3 Tesla scanner.
Study: NCT02473575

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine gum
Description: Gum is consumed 30 minutes before commencement of run

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo gum
Description: Gum is consumed 30 minutes before commencement of run
Study: NCT00515333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRx0014
Description: Hard capsule; 60 milligrams; t.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRx0014
Description: Hard capsule; 30 milligrams; t.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard capsule; 0 milligrams; t.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TRx0014
Description: Hard capsule, 100 milligrams, t.i.d.
Study: NCT02123407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon Nanoparticles
Description: Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy with D2 dissection
Description: In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.
Study: NCT01648777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L bupivacaine
Description: L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml~o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: * Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~* Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00
Study: NCT00453765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: montelukast, 8 weeks, once daily, 10 milligrams

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02385955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myeloablative double unit cord blood transplantation
Description: Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
Study: NCT01792999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced KBCT
Description: Contrast-enhanced KBCT includes pre-contrast KBCT scan and post-contrast KBCT scan. After the pre contrast scan is completed, a bolus injection of a low osmolar, nonionic, iodinated 300mg of iodine per mL contrast agent, will be injected at a rate of approximately 2.0 mL/s, for a total injection time of approximately 30-60 seconds. 30-60 seconds after the contrast injection, the post-contrast scan will be acquired.
Study: NCT03140527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active
Study: NCT01782677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Surgical Resection of Carotid Bodies
Study: NCT02126254

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic group
Description: NICAS guided treatment
Study: NCT03412643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly Paclitaxel
Description: 80 mg/m2 IV weekly for 12 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: loading dose of 8 mg/kg IV; then 6 mg/kg IV every 3 weeks for Cycles 2-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: loading dose of 840 mg IV; then 420 mg IV every 3 weeks for Cycles 2-4

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Celcuity CELx HSF
Description: Prior to drug interventions 3, 4,and 5, the Celcuity CELx HSF diagnostic test will be conducted to assess HER2 signaling activity
Study: NCT03140527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02665481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT03140527

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02665481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT03140527

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02665481

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Study: NCT03140527

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01351194

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic resection
Description: SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
Study: NCT02479425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient positioning
Description: positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient positioning
Description: positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
Study: NCT03977324

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chlorhexidine
Description: Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Connective Tissue Graft
Description: CTG will be positioned in the buccal aspect of the peri-implant tissue
Study: NCT03488381

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soccer Heading
Description: Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soccer Heading
Description: Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals.
Study: NCT00388518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos
Description: 45mg po daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.